BMRN vs. INCY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at BMRN and INCY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | BMRN | INCY |
|---|---|---|
| Company Name | BioMarin Pharmaceutical Inc. | Incyte Corporation |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Biotechnology |
| Market Capitalization | 11.19 billion USD | 16.76 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | July 26, 1999 | November 4, 1993 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of BMRN and INCY by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | BMRN | INCY |
|---|---|---|
| 5-Day Price Return | -1.95% | 9.78% |
| 13-Week Price Return | -5.00% | 41.08% |
| 26-Week Price Return | -9.39% | 14.54% |
| 52-Week Price Return | -34.52% | 40.46% |
| Month-to-Date Return | 0.78% | 14.63% |
| Year-to-Date Return | -11.30% | 24.29% |
| 10-Day Avg. Volume | 3.38M | 1.91M |
| 3-Month Avg. Volume | 2.22M | 1.94M |
| 3-Month Volatility | 27.90% | 36.33% |
| Beta | 0.34 | 0.74 |
Profitability
Return on Equity (TTM)
BMRN
11.48%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, BMRN’s Return on Equity of 11.48% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
INCY
24.09%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, INCY’s Return on Equity of 24.09% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
BMRN
21.45%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 21.45% places BMRN in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
INCY
18.99%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 18.99% places INCY in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
BMRN
25.33%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 25.33% places BMRN in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
INCY
25.80%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 25.80% places INCY in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | BMRN | INCY |
|---|---|---|
| Return on Equity (TTM) | 11.48% | 24.09% |
| Return on Assets (TTM) | 9.24% | 15.81% |
| Net Profit Margin (TTM) | 21.45% | 18.99% |
| Operating Profit Margin (TTM) | 25.33% | 25.80% |
| Gross Profit Margin (TTM) | 79.56% | 93.41% |
Financial Strength
Current Ratio (MRQ)
BMRN
5.56
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
BMRN’s Current Ratio of 5.56 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
INCY
2.85
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
INCY’s Current Ratio of 2.85 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
BMRN
0.10
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
BMRN’s Debt-to-Equity Ratio of 0.10 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
INCY
0.01
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
INCY’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
BMRN
-21.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
BMRN has a negative Interest Coverage Ratio of -21.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
INCY
6.86
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
INCY’s Interest Coverage Ratio of 6.86 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | BMRN | INCY |
|---|---|---|
| Current Ratio (MRQ) | 5.56 | 2.85 |
| Quick Ratio (MRQ) | 3.60 | 2.55 |
| Debt-to-Equity Ratio (MRQ) | 0.10 | 0.01 |
| Interest Coverage Ratio (TTM) | -21.18 | 6.86 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
BMRN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
BMRN
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
BMRN has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
INCY
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | BMRN | INCY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
BMRN
16.81
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
BMRN’s P/E Ratio of 16.81 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
INCY
18.99
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
INCY’s P/E Ratio of 18.99 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
BMRN
3.61
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, BMRN’s P/S Ratio of 3.61 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
INCY
3.61
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
In the lower quartile for the Biotechnology industry, INCY’s P/S Ratio of 3.61 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
BMRN
1.75
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
BMRN’s P/B Ratio of 1.75 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
INCY
3.16
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
INCY’s P/B Ratio of 3.16 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | BMRN | INCY |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 16.81 | 18.99 |
| Price-to-Sales Ratio (TTM) | 3.61 | 3.61 |
| Price-to-Book Ratio (MRQ) | 1.75 | 3.16 |
| Price-to-Free Cash Flow Ratio (TTM) | 15.99 | 17.26 |